An ERG gene break-apart assay, completed as previously described (Attard et al, 2008), demonstrated that an additional 155 cancers (36%) in this series contained ERG gene rearrangements, including one patient who had both ERG and ETV1 rearrangements in distinct foci of cancer in the same prostate, as reported previously (Attard et al, 2008; Clark et al, 2008). The gene discussed is ETV1; the disease is cancer.